New perspectives in the treatment of HBeAg‐positive and HBeAg‐negative chronic hepatitis B†

This publication has 26 references indexed in Scilit:

• A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-α2b and Lamivudine with Lamivudine Alone
  Annals of Internal Medicine, 2005
• Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
  The Lancet, 2005
• 424 Durability of HBEAG seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB)
  Journal of Hepatology, 2004
• Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
  New England Journal of Medicine, 2004
• Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B
  Journal of Viral Hepatitis, 2003
• Durability of Serologic Response After Lamivudine Treatment of Chronic Hepatitis B
  Hepatology, 2003
• Hepatitis B: Progress in the Last Decade
  Seminars in Liver Disease, 2003
• Results of lamivudine trials in Asia
  Journal of Hepatology, 2003
• Extended Lamivudine Treatment in Patients With Chronic Hepatitis B Enhances Hepatitis B E Antigen Seroconversion Rates: Results After 3 Years of Therapy
  Hepatology, 2001
• The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B
  Hepatology, 2000